8-K: Milestone Pharmaceuticals Advances CARDAMYST Towards FDA Approval with New PDUFA Date and Extended $75M Funding

Milestone Pharmaceuticals announced the FDA's acceptance of its response to the Complete Response Letter for CARDAMYST, setting a new PDUFA target action date of December 13, 2025, and extending its $75 million royalty purchase agreement with RTW through December 31, 2025.

Summary

• The U.S. Food and Drug Administration (FDA) has accepted Milestone Pharmaceuticals' response to issues raised in the Complete Response Letter (CRL) for CARDAMYST (etripamil) nasal spray.
• A new Prescription Drug User Fee Act (PDUFA) target action date of December 13, 2025, has been assigned for CARDAMYST, an investigational therapy for paroxysmal supraventricular tachycardia (PSVT).
• The existing Royalty Purchase Agreement with RTW Royalty I DAC, an affiliate of RTW Investments, LP, has been amended.
• The Marketing Approval Deadline for the $75.0 million purchase price under the Royalty Purchase Agreement has been extended from September 30, 2025, to December 31, 2025.
• The $75.0 million payment is contingent upon FDA approval of etripamil on or prior to December 31, 2025, and satisfaction of other customary closing conditions.
• Milestone received the CRL in March 2025 and held a Type A meeting with the FDA in early June 2025 to clarify outstanding items.
• The company submitted its response to the CRL on June 13, 2025, including results from additional in-vitro studies for nitrosamines and transferring manufacturing testing facility duties to vendors with recent FDA inspection history.
• The FDA has not raised any concerns regarding the clinical section of the New Drug Application (NDA).

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While there was a prior setback with the CRL and an implied delay, the FDA's acceptance of the response, the new PDUFA date, and the extension of significant contingent funding are strong positive indicators that the company is on track for potential approval and commercialization. The risks are standard for a biotech company awaiting drug approval.

Positives

• FDA acceptance of the response to the Complete Response Letter (CRL) for CARDAMYST is a significant step forward, indicating progress towards potential approval.
• A new PDUFA target action date of December 13, 2025, provides a clear timeline for a potential approval decision.
• The extension of the $75.0 million Royalty Purchase Agreement with RTW until December 31, 2025, ensures continued access to crucial funding for the planned commercial launch of CARDAMYST, contingent on FDA approval.
• The FDA has not raised any concerns regarding the clinical section of the NDA, suggesting the clinical efficacy and safety data are robust.
• The company successfully addressed the FDA's concerns regarding nitrosamines and manufacturing facility inspections, demonstrating responsiveness and capability.

Negatives

• The initial Complete Response Letter (CRL) in March 2025 indicated a delay in the approval process.
• The PDUFA date and the Royalty Purchase Agreement deadline have been extended, implying a delay from the original anticipated approval timeline.
• The $75.0 million funding is contingent upon FDA approval by December 31, 2025, and other closing conditions, meaning it is not guaranteed.

Risks

• Uncertain outcomes of future interactions with the FDA.
• Uncertainties related to the timing of initiation, enrollment, completion, evaluation, and results of clinical trials.
• Complexity inherent in cleaning, verifying, and analyzing trial data.
• Whether clinical trials will validate the safety and efficacy of etripamil for PSVT or other indications.
• General economic, political, and market conditions, including deteriorating market conditions due to investor concerns regarding inflation, Russian hostilities in Ukraine, and ongoing disputes in Israel and Gaza, and overall fluctuations in financial markets.
• Risks related to pandemics and public health emergencies.
• Risks related to the satisfaction of customary closing conditions for the $75 million purchase price under the Royalty Purchase Agreement.
• Sufficiency of Milestone's capital resources and its ability to raise additional capital in the current economic climate.

Future Outlook

Milestone Pharmaceuticals anticipates working with the FDA towards a potential approval decision for CARDAMYST later in 2025, with a PDUFA target action date of December 13, 2025. The company expects the $75.0 million in contingent funds from the Royalty Purchase Agreement to aid a successful planned commercial launch of CARDAMYST, if approved.

Management Comments

• "The FDA's acceptance for review of our response to the CRL is a key milestone for CARDAMYST and we look forward to working with the Agency toward a potential approval decision later this year."
• "We are also pleased, to amend our Royalty Purchase Agreement with RTW, underscoring their ongoing commitment to Milestone. The anticipated funds will position us well to execute on the commercial launch as we work to get CARADMYST into the hands of patients with PSVT in need of a new treatment."

Industry Context

This announcement positions Milestone Pharmaceuticals closer to bringing a novel, self-administered treatment for PSVT to market. The development of on-demand, patient-managed therapies like etripamil represents a growing trend in the pharmaceutical industry, aiming to improve patient convenience and reduce the burden on healthcare systems for episodic conditions. Successful approval would introduce a new competitor in the PSVT treatment landscape, potentially offering a differentiated option compared to existing acute care interventions.

Comparison to Industry Standards

• The document does not provide specific comparable companies, projects, or results to assess against global benchmarks.

Related Party Transactions

• Milestone Pharmaceuticals Inc. entered into an amendment to its existing Purchase and Sale Agreement with RTW Royalty I DAC, an affiliate of RTW Investments, LP, an existing shareholder.

Stakeholder Impact

• Shareholders: The FDA's acceptance and new PDUFA date reduce regulatory uncertainty and provide a clearer path to potential drug approval, which could positively impact share price. The extended funding agreement also provides financial stability.
• Patients: Potential approval of CARDAMYST offers a new, self-administered treatment option for paroxysmal supraventricular tachycardia (PSVT), potentially improving patient management and quality of life.
• RTW Investments, LP: As a key investor and partner in the Royalty Purchase Agreement, their commitment is reaffirmed by the extension, indicating continued confidence in CARDAMYST's potential.

Next Steps

• Work with the FDA towards a potential approval decision for CARDAMYST by the PDUFA target action date of December 13, 2025.
• Satisfy customary closing conditions for the $75.0 million purchase price under the Royalty Purchase Agreement upon potential FDA approval.
• Execute on the commercial launch of CARDAMYST following expected FDA approval.

Key Dates

Recommendation

Keywords

Milestone Pharmaceuticals, CARDAMYST, etripamil, FDA, PDUFA, Complete Response Letter, CRL, PSVT, paroxysmal supraventricular tachycardia, Royalty Purchase Agreement, RTW Investments, Nasal Spray, Drug Approval, Biopharmaceutical, Clinical Development, NDA